LONG MINI-FUTURE - NOVO-NORDISK B | Real-time Bid/Ask 12:32:31 2024-05-02 EDT | ||
| 20.2 EUR / 20.63 EUR | -0.56% |
|
| 1 month | -0.73% | ||
| 3 months | +21.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 21.12 | +2.87% | 0 |
| 24-04-30 | 20.53 | -0.44% | 0 |
| 24-04-29 | 20.62 | +1.83% | 0 |
| 24-04-26 | 20.25 | -0.05% | 0 |
| 24-04-25 | 20.26 | -2.50% | 0 |
Delayed Quote Börse Stuttgart
Last update May 02, 2024 at 02:17 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VN8X4X |
| ISIN | DE000VN8X4X2 |
| Date issued | 2017-04-10 |
| Strike | 115.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.55 € |
|---|---|
| Lowest since issue | 0.22 € |
| Spread | 0.43 € |
| Spread % | 2.08% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
897.7
DKK
Average target price
904.2
DKK
Spread / Average Target
+0.72%
- Stock Market
- Certificates
- Certificat
